Carter Gould

It’s been a rough couple of years for Gilead Sciences, Inc. (NASDAQ: GILD) investors, with the stock down more than 30 percent since early 2016. One analyst said Wednesday that Gilead may finally be turning the corner this year.  The Analyst UBS analyst Carter Gould upgraded Gilead...

Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...

Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside.  The Rating UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410. The Thesis Biogen’s...

Spark Therapeutics Inc (NASDAQ: ONCE) released phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. The Analyst UBS' Carter Gould downgraded Spark's stock rating from Buy to Neutral with a price target slashed from $92 to...

Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its efficacy targets. A handful of Wall Street analysts weighed in on Celgene stock following the news. Here’s...

The discontinuation of Celgene Corporation (NASDAQ: CELG)’s mongerson for Crohn’s disease prompted a 6.6-percent sell-off in Friday’s premarket trading. But UBS was undeterred by the announcement. “Looking forward, we are still encouraged by the prospects for this next...

Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn said the drug “could now be one of the first disease-modifying drugs to...

While risks to the stock still remain, UBS has upgraded Biogen Inc (NASDAQ: BIIB) from Sell to Neutral and has raised its price target for the stock from $262 to $270. At this point, the risks are fully priced into the stock, analyst Carter Gould wrote on Monday. “In our view, the competitive...

Barclays reiterated its Overweight rating on Acceleron Pharma Inc (NASDAQ: XLRN) after a meeting with management reinforced key elements of the firm's thesis on the company, particularly regarding the drug Luspatercept. Luspatercept And Acceleron's Recent Performance Acceleron's lead...